Oligonucleotides affecting expression of phosphodiesterases

Details for Australian Patent Application No. 2007252192 (hide)

Owner Topigen Pharmaceuticals Inc.

Inventors Renzi, Paolo; D'anjou, Helene; Paquet, Luc

Agent Spruson & Ferguson

Pub. Number AU-A-2007252192

PCT Pub. Number WO2007/134451

Priority 60/801,384 19.05.06 US

Filing date 18 May 2007

Wipo publication date 29 November 2007

International Classifications

C07H 21/00 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

Event Publications

18 December 2008 PCT application entered the National Phase

  PCT publication WO2007/134451 Priority application(s): WO2007/134451

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007252194-Method for monitoring and measuring optical properties of device in polarization maintaining fibers by using reference fiber Bragg grating and fiber components manufactured thereby

2007252183-Water solution of 20(R)-ginsenoside Rg3 pharmaceutical composition and process thereof